Member Info for JimiHendrix

This possibly suggests not all the costs of the test will be reimbursed by insurance companies. It would be useful to know how much can typically be expected to be reimbursed.

"Effective on 1 January for all requests for insurance reimbursement, whether from Medicare, Medicaid or private payors, this unique code will enable discussions regarding coverage decisions as well as negotiating the reimbursement rate."

I have the same niggles, I couldn’t find anything in the RNSs that would suggest the recent funding raise will cover the Oxford lab costs. In fact I can’t find any info about how much it will cost.

Yes, sold yesterday which means they will have likely gone over any threshold again today with the 40% increase in shareprice. Probably more selling from them to come though not a big problem at the moment whilst volume and liquidity is high.

Yes they have 10m left, I wonder if they're gradually selling the lot. I guess we'll find out over the coming days and weeks. I believe they're an investment fund, I can see why they'd take profit after a 400% rise.

SENECA PARTNERS LIMITED have sold 1.6m shares.

Thanks. Yes just read that Uncle, it doesn’t look as though the funding is specifically for the lab. It’s unclear if more is needed.

Do they have funding required for the Oxford lab facility that they are planning to open early next year? I’m just wondering if the likelihood they may raise more funds taking advantage of the huge rise in share price.

They're doing a good search marketing campaign. Their google ads are showing for a whole load of different search terms that customers will likely be searching for before and after taking a PSA test. Especially in the states.

Prostate biopsies can cost up to $2000 I believe, and when you consider the majority are unnecessary it begins to show the cost savings of using the PSE test.

Delayed buys from this morning, clearly a lot of orders being filled.

I’m coming from Genedrive so have seen tests launch with safety regulations cleared, but the key FDA, NICE, EU review etc comes later. I’m still researching OBD.

* FDA for US (I know that’s not needed for NHS!)

I’ve been reading through the RNSs, wondering whether it will be launched in Europe and if so do they have the necessary clinical trial data to get through EU regulations. Also will they be seeking FDA approval and UK NICE review in order for NHS doctors to use the test? I understand NHS doctors need NUCE guidance recommendation before they can routinely adopt a test.

First 200k is a buy and the second is a sell, I’d guess the same person making a quick bit of profit.

Thanks! Are there any plans to have NICE review it? I can’t see anything mentioned in the RNSs.

Does this have NICE guidance yet for the NHS? I can’t see that it does.

The 3 million buyer is still in. There’s also been a few large buys on the pull back. Market cap is still very very small here.

To be fair though Nissan, they said the same thing about 'accelerating sales' with AIHL final NICE recommendation.

My view at the moment is we can say with reasonable confidence that we have funding until March. We don't know if the DEVOTE funding will affect existing monthly cash burn or how much it will be and when/how we'll receive it. Also at the moment we can't be sure when or if the monthly drawdowns will resume.

This also doesn't include funding required for FDA submission, if they go ahead with that they'll need another 2m GBP I believe. It's not looking great here at the moment to be honest though I expect we'll see a decent boost in share price in December regarding the stroke marker test.

JohnHenry, I believe they only receive warrants if the drawdowns are made. Interest is payable if the monthly drawdowns of 300k are not made. It's all in the circular.